Accepted Manuscript

Title: Tuberculin Skin Test – outdated or still useful for Latent TB Infection screening?

Authors: Gina Gualano, Paola Mencarini, Francesco Nicola Lauria, Fabrizio Palmieri, Sayoki Mfinanga, Peter Mwaba, Jeremiah Chakaya, Alimuddin Zumla, Giuseppe Ippolito

PII: S1201-9712(19)30061-X
DOI: https://doi.org/10.1016/j.ijid.2019.01.048
Reference: IJID 3480

To appear in: International Journal of Infectious Diseases

Received date: 8 January 2019
Revised date: 24 January 2019
Accepted date: 31 January 2019

Please cite this article as: [https://doi.org/]

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
REVISED ARTICLE

TITLE:
Tuberculin Skin Test – outdated or still useful for Latent TB Infection screening?

AUTHORS:
Gina Gualano¹, Paola Mencarini¹, Francesco Nicola Lauria¹, Fabrizio Palmieri¹, Sayoki Mfinanga²,³, Peter Mwaba⁴, Jeremiah Chakaya⁵, Alimuddin Zumla⁶, Giuseppe Ippolito¹

INSTITUTIONAL AFFILIATIONS:
¹National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
²National Institute for Medical Research Muhimbili, Dar es Salaam, Tanzania.
³Liverpool School of Tropical Medicine, Liverpool, UK
⁴UNZA-UCLMS Project, and Lusaka Apex University Medical School, Lusaka, Zambia.
⁵International Union Against TB and Lung Diseases, Paris, France; Department of Medicine, Kenyatta University, Nairobi, Kenya.
⁶Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, & NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.

Gina Gualano MD: National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
Electronic mail: gina.gualano@inmi.it;

Paola Mencarini, MD: National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy.
Electronic mail: paola.mencarini@inmi.it;
Francesco Nicola Lauria MD: National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy. Electronic mail: francesco.Lauria@inmi.it;

Fabrizio Palmieri MD: National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy. Electronic mail: fabrizio.palmieri@inmi.it;

Sayoki Mfinanga MD. National Institute for Medical Research Muhimbili, Dar es Salaam, Tanzania. Electronic address: gsmfinanga@yahoo.com;

Peter Mwaba FRCP. UNZA-UCLMS Project, and Lusaka Apex University Medical School, Lusaka, Zambia. Electronic address: pbmwaba2000@gmail.com;

Jeremiah Chakaya MD. International Union Against TB and Lung Diseases, Paris, France; Department of Medicine, Kenyatta University, Nairobi, Kenya. Electronic address: chakaya.jm@gmail.com;

Alimuddin Zumla MD, Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, & NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK. Electronic mail: a.i.zumla@ucl.ac.uk;

Giuseppe Ippolito MD, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome: giuseppe.ippolito@inmi.it;

Corresponding author: Giuseppe Ippolito MD, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome: giuseppe.ippolito@inmi.it

HIGHLIGHTS

- Tuberculin skin test (TST) is over a century old but it continues to be used widely.
• When IGRAs were introduced it was anticipated that they would rapidly replace TST.
• Neither TST nor IGRAs have a high accuracy for predicting active TB.
• Latest WHO recommendation are that either TST or IGRA can be used to test for LTBI.
• TST will be clinically useful until more accurate tests become available.

ABSTRACT

Objective: To make an informed viewpoint on the usefulness of Tuberculin Skin test (TST) compared to Interferon Gamma Release Assays (IGRAs) for diagnosis of Latent TB Infection (LTBI) in different geographical settings.

Methods: We reviewed the current literature on TST compared to IGRA, including national implementation of WHO LTBI recommendations and retrospective data over the past 7 years at the National Institute for Infectious Diseases “L. Spallanzani” as indirect indicator of usage of both tests under actual programmatic conditions.

Results: Current national guidelines vary considerably, reflecting the uncertainty and rapidly evolving evidence about the potential use of these tests. Data from Institute “L. Spallanzani” showed IGRA concordance in TST positive subjects only in 54.74% of subjects, while there was strong concordance between two tests in TST negative subjects (93.78%).

Conclusion: Neither IGRAs nor TST can distinguish active TB from LTBI. TST will continue to be clinically useful in low and high TB endemic areas until more accurate and predictive tests will become available. Clinical judgment remains fundamental in choosing between IGRA/TST tests and interpreting their results.

Introduction
Whilst the tuberculin skin test (TST) (better known as the Mantoux Test to older generation physicians), is over a century old, it continues to be used in high endemic TB settings as diagnostic tool for determining latent *Mycobacterium tuberculosis* (MTB) infection (LTBI) (1). WHO define latent tuberculosis infection as “a state of persistent immune response to stimulation by *Mycobacterium tuberculosis* antigens with no evidence of clinically manifest active TB”. The TST measures delayed type hypersensitivity (DTH) response to intradermal injection of purified protein derivative (PPD), a crude mixture of several mycobacterial antigens, which are common to *M. tuberculosis*, *M. bovis* BCG, and non-tuberculous mycobacteria (NTM). Thus, a positive TST test is of low specificity and cannot differentiate between *M. tuberculosis* infection, prior BCG vaccination, infection with, or exposure to NTM. It also has a low sensitivity in individuals with immunosuppression such as people living with HIV. Operational limitations of test include requirement for two visits up to 72 hours apart, between initial intradermal injection of PPD to reading the skin PPD-DTH response, reader variability, and the need for trained personnel to read the test results.

**Interferon-γ release assays versus TST**

While TST encompasses antigens recognized by a vast pool of circulating T lymphocytes, the two interferon-γ release assays (IGRAs), the QuantiFERON-TB ® assay (Cellestis Limited, Australia) and T SPOT-TB ® (Oxford Immunotec, UK), focus on interferon-γ responses to epitopes from two specific MTB complex associated antigens, namely ESAT-6 and CFP-10. When IGRAs were introduced into clinical practice a decade ago, it was anticipated that they would rapidly replace TST which would become redundant. The reasons were that: IGRAs do not cross-react with BCG, they are less likely to cross-react with NTM and they require only one health-care visit during which a blood sample is drawn and results can be available within 24 hours. Disadvantages of IGRAs are that they require blood samples and a laboratory to process them, quickly after collection (2). While hundreds of papers have been published on comparing performance of TST and IGRAs much remains unknown about the efficacy of IGRAs relative to TST due
methodological limitations, the lack of a compactor gold standard for detecting LTBI and the small sample size and inadequate statistical power (3). IGRAs appear to have a higher specificity than TST in persons vaccinated with BCG, although they have similar sensitivity to TST.

**TST versus IGRAs for predicting the risk of LTBI progressing to active TB disease**

A large prospective cohort study in the United Kingdom showed that positive IGRAs were significantly better than the TST-10 mm and TST-5 mm strategies in predicting the development of active TB among high-risk individuals from TB-endemic countries. TST-5 mm identified a higher proportion of participants who progressed to active TB (64 [83%] of 77 tested) than all other tests and TST thresholds (≤75%) (4). Several published studies have addressed these issues with different results and conclusions: Pai and coll. reported a pooled specificity of 99% among non-BCG vaccinated and 96% among BCG-vaccinated low-risk groups (5). Vesembecht and colleagues assessed the diagnostic accuracy (21% of controls showed test results above 0.35 IU/mL) of the latest generation IGRA in low-incidence areas in Germany (6). In a recent meta-analysis by Sester and colleagues not restricting studies on specificity to low-risk groups (a situation that is closer to the clinical setting), the specificity of QFT-GIT was only 0.79 (95% CI 0.75–0.82). (7). Rangaka and colleagues systematic review and meta-analysis showed neither TST nor IGRAs have a high accuracy for predicting active TB (8).

**Latest WHO guidelines for use of TST and IGRAs**

The WHO guidelines Group for developing the WHO LTBI management guidelines (WHO, 2018) utilized five IGRA and TST studies from high-TB incidence countries estimated pooled Risk Ratios for test positives and test negatives for each test and found RR 1.49 for TST and 2.03 for IGRA. They concluded that neither test is better for predicting progression to active TB disease and that TST remains an acceptable option for children of less of five years old (1). In HIV-infected individuals, a recent review of comparative
data did not provide robust evidence to support the assertion that the IGRAs are superior to the TST when used in HIV infected subjects without evidence of active TB (9).

Generic WHO recommendation are that either TST or IGRA can be used to test for LTBI. Persons with no known risk factors for TB may be considered for treatment of LTBI if they have a positive skin reaction to the TST of 15 mm or larger.

There is no strong evidence that one test should be preferred over the other to predict progression to active TB disease. IGRAs or TST in clinical practice should be guided by considerations of availability, cost and benefits, and resources (1). European Centre for Disease Prevention and Control’s evaluation of cost-effectiveness of screening, from the healthcare perspective, was in favor of using TST, and if positive followed IGRA (10). An official CDC health update highlighted higher costs associated at the use of the IGRA blood tests as substitute for TSTs (11). Other countries, such as England, recommend using TST in BCG- vaccinated subjects. (12)

**National guidelines for use of TST or IGRAs**

Current national guidelines vary considerably, reflecting the uncertainty and rapidly evolving evidence about the potential uses of these tests (13). In deciding whether to use the TST, IGRAs individual clinical expertise and the best available local evidence are essential tools for developing local guidelines. At the National Institute for Infectious Diseases “L. Spallanzani” in Rome since several years, a protocol for the management of tuberculosis (available at http://www.inmi.it/protocolli_e_linee_guida.html), based on WHO and ECDC recommendations, was adopted. The protocol recommends the use of IGRAs tests in subjects vaccinated with BCG (or coming from countries where the vaccination is routinely performed), in immunosuppressed patients (HIV, especially if CD4 + <200/ mmc, or taking immunosuppressive drugs), children >5 years and, according to the clinician opinion, as a TST confirmation test. Observational routinely collected health data in the last 7 years have been evaluated as indirect indicator of test’s performance under real-life conditions and are summarized hereafter as end-users’ report.
From January 2011 to November 2018, in 6,132 subjects TST (PPD-S 5UI) had been performed with 1,329 positive tests after 72 hours (21.67%). Applying this protocol, IGRA (QuantiFERON-TB ®) test was performed in 346 subjects from this cohort, with 88 positive results (25.43%). Data reported in Table 1 demonstrate clinical use of IGRA test as a confirmatory test in 60.40% of TST- subjects and in 39.60% of TST+ subjects. While IGRA concordance in TST+ve subjects was observed in 54.74% of subjects, data showed strong concordance between two tests in TST-ve subjects, in which group HIV/Immunosuppressed patients are mostly represented. These data are consistent with the local protocol statement who suggest carefully evaluate negativity of TST/IGRA in immunosuppressed patients, especially in ruling out active TB. In our experience, although not in a very large number of patients, IGRAs were able to identify 13 out of 209 individuals (6.22%) candidates to LTBI treatment who were TST negative. These data must be interpreted cautiously considering high variability of context in real life, and need to be confirmed by further studies. In fact, choice of one test or both and interpretation of their results need to be defined considering the clinical or epidemiological characteristics of the subjects, available resources and turn-round time.

**Conclusion**

Clinical use of the TST as opposed to IGRAs should be according to availability of reagents, resources, national recommendations, specific clinical scenario. Clinical judgement remains fundamental in selecting the LTBI tests, interpreting the results of IGRA/TST tests. The ultimate test awaited is one that can more specifically distinguish active TB from LTBI. The use of IGRAs has increased in low TB endemic areas but TST will continue to be clinically useful in low and high TB endemic areas, until more predictive tests become available to allow for identification of individuals at the highest risk of progressing to developing active TB diseases.

**Conflicts of Interest:** All authors declare no conflict of interest
Contributions

FNL, AZ and GI conceived the idea and developed key concepts in the manuscript, contributed to the literature review, the first draft and revisions of the manuscript. GG, PMe, FP collected and analyzed data, contributed to the literature review, the first draft and revisions of the manuscript. SM, PMw, JC contributed to the original text and subsequent revisions of the manuscript. All authors read and approved the final manuscript.

Ethical approval

All enrolled patients provided written informed consent to the utilization of anonymous clinical data for research purpose approved by L. Spallanzani Institute Ethical Committee.

Acknowledgements

Authors GG, PMe, FNL, FP, and GI are grateful for support from the Italian Ministry of Health, grant Ricerca Corrente, Research program n. 4 Tuberculosis. Original data to evaluate in the real life the Concordance of TST and IGRA have been collected in the framework of the Ricerca Corrente funding.

Authors SM, PMw, AZ and GI receive support from EDCTP2 grants (RIA 2016E-1609-PANDORA-IDNET and EDCTP-RegNet2015-1104 EACCR2) supported under Horizon 2020, the European Union.
References


Table 1. Concordance of TST and IGRA results among subjects referred at National Institute for Infectious Diseases Lazzaro Spallanzani in Rome

<table>
<thead>
<tr>
<th></th>
<th>IGRA +</th>
<th>IGRA -</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TST+ n. (%)</strong></td>
<td>75 (54.74%)</td>
<td>62 (45.26%)</td>
<td>137 (39.60%)</td>
</tr>
<tr>
<td></td>
<td>BCG Vaccinated 45</td>
<td>BCG Vaccinated 39</td>
<td>BCG vaccinated 84</td>
</tr>
<tr>
<td></td>
<td>Clinician opinion 26</td>
<td>Clinician opinion 22</td>
<td>Clinician opinion 48</td>
</tr>
<tr>
<td></td>
<td>HIV/Immunosuppressed 4</td>
<td>HIV/Immunosuppressed 1</td>
<td>HIV/Immunosuppressed 5</td>
</tr>
<tr>
<td></td>
<td>Children &gt; 5 years 0</td>
<td>Children &gt; 5 years 0</td>
<td>Children &gt; 5 years 0</td>
</tr>
<tr>
<td><strong>TST- n. (%)</strong></td>
<td>13 (6.22%)</td>
<td>196 (93.78%)</td>
<td>209 (60.40%)</td>
</tr>
<tr>
<td></td>
<td>BCG Vaccinated 2</td>
<td>BCG Vaccinated 74</td>
<td>BCG Vaccinated 76</td>
</tr>
<tr>
<td></td>
<td>Clinician opinion 8</td>
<td>Clinician opinion 102</td>
<td>Clinician opinion 110</td>
</tr>
<tr>
<td></td>
<td>HIV/Immunosuppressed 3</td>
<td>HIV/Immunosuppressed 20</td>
<td>HIV/Immunosuppressed 23</td>
</tr>
<tr>
<td></td>
<td>Children &gt; 5 years 0</td>
<td>Children &gt; 5 years 0</td>
<td>Children &gt; 5 years 0</td>
</tr>
<tr>
<td><strong>IGRA n. (%)</strong></td>
<td>88 (25.43%)</td>
<td>258 (74.57%)</td>
<td>346</td>
</tr>
</tbody>
</table>

TST: Tuberculin Skin Test

IGRA: interferon-γ release assay (QuantiFERON-TB Gold In-Tube)

BCG: Calmette Guèrin Bacillus